Oxford Nanopore Technologies Plc
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Semi-annual Revenue
•
in mil. unless spec.Semi-annual Earnings Per Share
•
in mil. unless spec.Semi-annual Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Francis Albert Luc van Parys
- Full Time Employees
- 1,403
- Sector
- Electronic technology
- Industry
- Electronic equipment/Instruments
- Address
- Gosling Building Oxford OX United Kingdom OX4 4DQ
- IPO Date
- Sep 30, 2021
- Website
- nanoporetech.com
- Similar Companies
- Business
- Oxford Nanopore Technologies plc Oxford Nanopore Technologies plc develops and commercializes nanopore-based molecular sensing technology for DNA and RNA sequencing, enabling real-time analysis of native molecules with short to ultra-long read lengths in portable to high-throughput formats. The company offers a suite of sequencing devices including the palm-sized MinION for field and lab use, Flongle for smaller on-demand tests, benchtop GridION supporting up to five MinION Flow Cells, and PromethION platforms including the compact PromethION 2 for up to 48 Flow Cells generating over 10 Tb of data per run; complementary products encompass rapid library preparation kits such as a 10-minute protocol, flow cells, and analysis software like EPI2ME workflows for genomics, transcriptomics, metagenomics, epigenomics, and multi-omics applications. Oxford Nanopore Technologies plc serves scientific research in human genetics, cancer, infectious diseases, microbiology, environmental monitoring, and agriculture; clinical and applied markets including diagnostics, epidemiology, and personalized medicine; with customers spanning academia, biopharma, healthcare, and industry across more than 120 countries. Founded in 2005 as a spin-out from the University of Oxford and headquartered at the Oxford Science Park in Oxford, UK, the company maintains satellite offices in Cambridge UK, multiple US locations, Singapore, Shanghai, Beijing, and commercial presence in Japan, Germany, France, and India, supported by over 1,000 employees and a patent portfolio exceeding 2,600 filings. Recent developments include the October 2025 expansion of its agreement with Bio-Techne through 2032 to develop and commercialize a broader portfolio of genetics products building on the March 2025 launch of the AmplideX Nanopore Carrier Plus Kit for heritable disorder screening; April 2025 enlargement of the Compatible Products Programme adding partners such as 10x Genomics, Agilent Technologies, Thermo Fisher Scientific, and others to enhance multi-omics workflows with single-cell, spatial biology, automation, and reagents; a new strategic partnership with Cepheid for automated infectious disease sequencing solutions; alongside innovations in basecalling, real-time methylation detection, direct RNA multiplexing, and early proteomics progress as of H1 2025 when revenue rose 26% to £105.6 million.
Company News
IP Group banks £21m in Oxford Nanopore divestment
Oxford Nanopore target price raised by RBC on AI opportunity
Oxford Nanopore Technologies plc (OXFYY) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Oxford Nanopore target price hiked to 196p by Panmure Liberum on strategic pivot
Oxford Nanopore Technologies plc (OXFYY) Q2 2026 Earnings Call Transcript
Oxford Nanopore Technologies H1 Earnings Call Highlights
Oxford Nanopore sets $700m revenue target for 2030
Oxford Nanopore shares slide 16% after first-half sales miss expectations
Leading banks back Oxford Nanopore after London Calling showcases maturing platform
Oxford Nanopore and A.D.A.M. Innovations Announce International Collaboration to Accelerate Advanced Genomic Medicine in Japan
Oxford Nanopore Technologies plc (ONTTF) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
ViruSure Launches First GMP-Validated Viral Safety Test Based on Oxford Nanopore Sequencing
Citi keeps 'buy' rating on Oxford Nanopore as profitability target holds despite revenue miss
Oxford Nanopore Technologies plc (ONTTF) Q4 2025 Earnings Call Transcript
Oxford Nanopore Technologies plc (ONTTF) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Oxford Nanopore rises on strong 2025 revenue growth
Oxford Nanopore Receives Regulatory Approval for its First Diagnostic Device in the UK and Europe
Oxford Nanopore Technologies plc (ONTTF) Presents at Citi Annual Global Healthcare Conference 2025 Transcript
Oxford Nanopore Announces PromethION Plus Flow Cell and Human Genetics Updates at ASHG 2025
Bio-Techne and Oxford Nanopore Technologies Expand Agreement to Accelerate Development of Genetics Portfolio Through 2032